1. 59PDFinal analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. (23rd October 2018) Authors: Finn, R S; Kudo, M; Cheng, A-L; Wyrwicz, L; Ngan, R; Blanc, J F; Baron, A D; Vogel, A; Ikeda, M; Piscaglia, F; Han, K-H; Qin, S; Minoshima, Y; Kanekiyo, M; Ren, M; Dairiki, R; Tamai, T; Dutcus, C E; Funahashi, Y; Evans, T R J Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 76PCorrelative analyses of serum biomarkers and efficacy outcomes in the randomized phase II trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma. (23rd October 2018) Authors: Lee, C-H; Motzer, R J; Glen, H; Michaelson, M D; Larkin, J; Minoshima, Y; Kanekiyo, M; Dairiki, R; Sachdev, P; Dutcus, C E; Funahashi, Y; Voss, M H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗